InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,610.00
(
0.00%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.22
(
-0.31%
)
Bitcoin
63,755.24
(
0.93%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 250

Tuesday, 07/17/2018 9:04:33 AM

Tuesday, July 17, 2018 9:04:33 AM

Post# of 438
ACRX may benefit from legislation that allows DOD to use medical products that are unapproved by the FDA.

Rather than cede control of a group of treatments to another agency, FDA has agreed to expedite development and review of treatments upon Secretary of Defense request.

As a result, DSUVIA is in a much stronger position for approval for its 11/3/18 PDUFA.

Watch for an October Adcom.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up